


PHARMACEUTICAL 2022



MARIZYME INC. Rank 191 of 466







PHARMACEUTICAL 2022



MARIZYME INC. Rank 191 of 466

The relative strengths and weaknesses of MARIZYME INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MARIZYME INC. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 366% points. The greatest weakness of MARIZYME INC. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 83% points.

The company's Economic Capital Ratio, given in the ranking table, is 168%, being 91% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	4,402
Cost of Goods Sold	0
Intangible Assets	60,057
Liabilities, Current	3,134
Liabilities, Non-Current	15,175
Other Assets	1,528
Other Compr. Net Income	0
Other Expenses	7,350
Other Liabilities	0
Other Net Income	-2,177
Other Revenues	210
Property and Equipment	13
Research and Development	1,682
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	65,999
Liabilities	18,309
Expenses	9,032
Revenues	210
Stockholders Equity	47,690
Net Income	-10,998
Comprehensive Net Income	-10,998
Economic Capital Ratio	168%

